Hyrimoz (adalimumab-adaz) — FDA-Approved Biosimilar to Humira (adalimumab)
TNF-alpha Inhibitor Biosimilar · Approved 2018 · $0–$35/mo for most insured patients
🔬 What Is Hyrimoz?
Hyrimoz (adalimumab-adaz) is an FDA-approved biosimilar to Humira (adalimumab). A biosimilar is a biological medication that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Hyrimoz (adalimumab-adaz) is a Sandoz FDA-approved Humira biosimilar available in both standard and high-concentration citrate-free formulations. Sandoz is a leading global biosimilar manufacturer, and Hyrimoz is approved for all Humira indications.
🛒 Order Hyrimoz — Direct from BiologicHealthPlus
Our pharmacist team will contact you within 2 hours to verify your prescription and insurance.
With Insurance
$0–$35/mo for most insured patients
Sandoz One Source
Uninsured / PAP
Free
Income-based assistance
Hyrimoz Overview
| Property | Details |
|---|---|
| Brand Name | Hyrimoz |
| Generic Name | adalimumab-adaz |
| Reference Biologic | Humira (adalimumab) |
| Manufacturer | Sandoz |
| Drug Class | TNF-alpha Inhibitor Biosimilar |
| FDA Approval | 2018 |
| Route | Subcutaneous injection |
| Approved Conditions | Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, HS, Uveitis, JIA |
| Copay Program | Sandoz One Source — $0–$35/mo for most insured patients |
Approved Conditions
Hyrimoz vs Humira (adalimumab)
Hyrimoz has been demonstrated to be biosimilar to Humira (adalimumab) through comprehensive analytical, non-clinical, and clinical studies. The FDA requires that biosimilars have no clinically meaningful differences from the reference product. Patients who are stable on Humira (adalimumab) should discuss any potential switch to Hyrimoz with their prescriber.
| Factor | Hyrimoz | Humira (adalimumab) |
|---|---|---|
| FDA Status | Biosimilar (approved 2018) | Reference biologic |
| Active Ingredient | adalimumab-adaz | adalimumab |
| Mechanism | TNF-alpha Inhibitor | Same |
| Approved Indications | Same as Humira (adalimumab) | Multiple FDA-approved |
| Typical Patient Cost | $0–$35/mo for most insured patients | $0–$35/mo (varies by plan) |
📚 Sources & Further Reading
Medical Disclaimer: Educational content reviewed by BiologicHealthPlus Clinical Team. Last reviewed: August 2026.